Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Primary Health Care Research & Development
|
May 30, 2013
Variations in primary care prescribing: lessons to be learnt for GP commissioners
Rachel Houten, Allan Wailoo, Pall Jonsson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 24, 2018
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Christopher Carroll, Rachel Houten, Angela Boland, et al.
Pharmacoeconomics
|
August 15, 2014
Through a glass darkly: economics and personalised medicine
Alan Haycox, Munir Pirmohamed, Claire McLeod, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
October 24, 2020
A systematic review of health state utility values for thyroid cancer
Rachel Houten, Nigel Fleeman, Eleanor Kotas, et al.
Pharmacoeconomics - Open
|
March 25, 2020
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Angela Stainthorpe, Nigel Fleeman, Rachel Houten, et al.
Neuromodulation : Journal of the International Neuromodulation Society
|
April 9, 2022
Spinal Cord Stimulation for Neuropathic Pain in England From 2010 to 2020: A Hospital Episode Statistics Analysis
Rui V Duarte, Sarah Nevitt, Rachel Houten, et al.
BMC Cancer
|
December 14, 2019
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Nigel Fleeman, Rachel Houten, Marty Chaplin, et al.
Pharmacoeconomics - Open
|
September 21, 2023
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, et al.
Pharmacoeconomics - Open
|
April 16, 2020
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Rachel Houten, Janette Greenhalgh, James Mahon, et al.
Journal of Clinical Apheresis
|
September 30, 2015
Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial
Antony P Martin, Sarah Richards, Alan Haycox, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Primary Health Care Research & Development
|
May 30, 2013
Variations in primary care prescribing: lessons to be learnt for GP commissioners
Rachel Houten, Allan Wailoo, Pall Jonsson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 24, 2018
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Christopher Carroll, Rachel Houten, Angela Boland, et al.
Pharmacoeconomics
|
August 15, 2014
Through a glass darkly: economics and personalised medicine
Alan Haycox, Munir Pirmohamed, Claire McLeod, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
October 24, 2020
A systematic review of health state utility values for thyroid cancer
Rachel Houten, Nigel Fleeman, Eleanor Kotas, et al.
Pharmacoeconomics - Open
|
March 25, 2020
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Angela Stainthorpe, Nigel Fleeman, Rachel Houten, et al.
Neuromodulation : Journal of the International Neuromodulation Society
|
April 9, 2022
Spinal Cord Stimulation for Neuropathic Pain in England From 2010 to 2020: A Hospital Episode Statistics Analysis
Rui V Duarte, Sarah Nevitt, Rachel Houten, et al.
BMC Cancer
|
December 14, 2019
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Nigel Fleeman, Rachel Houten, Marty Chaplin, et al.
Pharmacoeconomics - Open
|
September 21, 2023
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, et al.
Pharmacoeconomics - Open
|
April 16, 2020
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Rachel Houten, Janette Greenhalgh, James Mahon, et al.
Journal of Clinical Apheresis
|
September 30, 2015
Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial
Antony P Martin, Sarah Richards, Alan Haycox, et al.
Page
of 2